Predicting response to checkpoint inhibitors requires more than a crystal ball

Routine blood tests such as leucocyte counts and lactate dehydrogenase (LDH) along with clinical markers such as adverse events may play a role in predicting response and toxicity to immune checkpoint inhibitors (ICIs). However most of the evidence is currently restricted to ipilimumab in the treatment of advanced melanoma and more research is required as ...